Chris Gordon

Chris Gordon is a Partner at Bain Capital, a leading global private investment firm with over $160 billion in assets under management.  Mr. Gordon joined Bain Capital in 1997. He is Co-Head of Bain Capital’s North America Private Equity business and Global Head of the Healthcare Industry Vertical.

Since joining the firm in 1997, Mr. Gordon has been actively involved in and served on the Board of Directors for a wide spectrum of prominent healthcare companies in which Bain Capital has made investments. Current and former directorships include HCA Inc. (NYSE: HCA), the world’s largest private-sector operator of acute care hospitals; Quintiles Transnational Corporation (now IQVIA), the world’s leading provider of contract research and other services to the pharmaceutical sector; Grupo Notre Dame Intermedica, one of Brazil’s leading health and dental managed care providers delivering care through an integrated platform; Air Medical Group Holdings, Inc., the largest independent provider of emergency air medical transport services; Acadia Healthcare Company Inc. (Nasdaq: ACHC), the largest dedicated provider of facilities-based and outpatient behavioral health services;  Beacon Health Options, a leading manager of behavioral health benefits on behalf of payors and government entities; Physio Control, Inc., the world’s leading provider of professional external defibrillators and other emergency medical response solutions; QuVa Pharmaceuticals, an emerging provider of sterile admixing services and pre-packaged pharmaceutical preparations to the hospital sector; Waystar, Inc., a leading provider of revenue cycle management and healthcare analytics software for hospitals and physician practices, Aveanna, a leading provider of pediatric home nursing and related services, Surgery Partners (Nasdaq: SGRY), the leading independent operator of Ambulatory Surgery Centers and Physician-owned hospitals, Stada GMBH, a leading European generic pharmaceutical business, US Renal Care, a leading dialysis operator, and Cerevel Therapeutics, a platform created by Bain Capital and Pfizer to develop novel CNS pharmaceuticals.

Prior to joining Bain Capital, Mr. Gordon was a consultant at Bain & Company. He is a founding Director of the Healthcare Private Equity Association. Mr. Gordon also volunteers his time and support to a variety of charitable organizations. Mr. Gordon serves as a member of the Board of Directors of Year Up, Tenacity Inc and the Boston Medical Center Health Plan, and as a member of the Dana Farber Cancer Institute Board of Trustees.

Mr. Gordon received an AB in Economics from Harvard College graduating magna cum laude and an MBA from Harvard Business School where he was a Baker Scholar.